Loading
Spanish breast oncologist leading DESTINY-Breast09, which moved trastuzumab deruxtecan into first-line HER2-positive disease.
Cristina Saura led NALA (neratinib plus capecitabine) and is a principal investigator of DESTINY-Breast09, the trial showing trastuzumab deruxtecan plus pertuzumab outperforms the CLEOPATRA regimen first line. She heads breast cancer at Vall d'Hebron, is active in the SOLTI cooperative group, and works on ctDNA and brain-metastasis strategies in HER2-positive disease.
| Title | Journal | Year |
|---|---|---|
| Neratinib plus capecitabine versus lapatinib plus capecitabine in HER2-positive metastatic breast cancer previously treated with two or more HER2-directed regimens (NALA) | JCO | 2020 |
| Trastuzumab deruxtecan plus pertuzumab for first-line HER2-positive advanced breast cancer (DESTINY-Breast09) | NEJM | 2025 |
Shares Trastuzumab deruxtecan, HER2, HER2-positive breast cancer, Antibody-drug conjugate (ADC) and the tags breast, her2, adc.
Shares Trastuzumab deruxtecan, HER2, HER2-positive breast cancer, Antibody-drug conjugate (ADC) and the tags breast, adc.
Shares HER2, HER2-positive breast cancer and the tags breast, her2.
Shares HER2, HER2-positive breast cancer and the tags breast, her2.
Shares Antibody-drug conjugate (ADC) and the tags breast, adc.
Shares Vall d'Hebron University Hospital / VHIO, HER2, HER2-positive breast cancer.
Shares Trastuzumab deruxtecan, HER2, Antibody-drug conjugate (ADC) and the tag breast.
Shares SOLTI Cancer Research Group, HER2-positive breast cancer.